LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global factor VIII deficiency treatment market is projected to grow to USD 11 billion, at a CAGR of close to 6% ...

DUBLIN--(BUSINESS WIRE)--The "Hemophilia a (Factor Viii Deficiency) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. The report enhances the ...

Dublin, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The "Hemophilia A (Factor VIII Deficiency) - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This ...

The European Medicines Agency (EMA) this week recommended granting a marketing authorization for Altuvoct (efanesoctocog alfa) for the treatment and prophylaxis of bleeding in patients with hemophilia ...

Altuviiio temporarily replaces the missing coagulation factor VIII needed for effective hemostasis. The Food and Drug Administration (FDA) has approved Altuviiio ™ (antihemophilic factor [recombinant] ...

Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The "Coagulation Factor Deficiency Market - A Global and Regional Analysis: Focus on Deficiency Type, Product Type, End-User, and Region - Analysis and ...

There are two main types of hemophilia - Hemophilia A (due to factor VIII deficiency) and Hemophilia B (due to factor IX deficiency). They are clinically almost identical and are associated with ...

With its new FDA approval, Hemlibra (emicizumab-kxwh), a bispecific factor IXa- and factor X-directed antibody, has become the first prophylactic treatment for patients with hemophilia A with or ...

Hemophilia is characterized by genetic mutations resulting in the deficiency of factors critical to the normal process of coagulation, sometimes resulting in spontaneous bleeding into soft tissue, ...

Pfizer disclosed a patient death in a marstacimab hemophilia study, triggering a safety review and reassessment of surgical ...

VON Willebrand's disease is manifested by a deficiency of factor VIII (antihemophilic factor) and a prolonged bleeding time and is inherited as an autosomal dominant trait of variable penetrance. 1 ...